Clinical trial · Interventional
Gemcitabine With Curcumin for Pancreatic Cancer
Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer
NCT00192842CI-TRIAL-00003954completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| curcumin (+ gemcitabine) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- time to tumor progression
Secondary outcomes (4)
- measure
- response rate
- measure
- survival
- measure
- clinical benefit
- measure
- toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * locally advanced or metastatic adenocarcinoma of the pancreas * no prior chemotherapy * performance status 0-2 * adequate hematology and chemistry Exclusion Criteria: * serious concurrent medical condition
References
Publications (0)
Data not yet available
No reference posted for this study.